Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy
Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma
What is follicular lymphoma?
Follicular lymphoma is a slow growing cancer of B lymphocytes and the second most common non-Hodgkin lymphoma, about 20 percent of cases, usually diagnosed in people in their 60s. It often shows up as painless swollen lymph nodes and may cause no symptoms for years, so people with low tumor burden are often watched rather than treated at first. When treatment is needed, it usually combines an anti CD20 antibody with chemotherapy or lenalidomide, and early stage disease may be treated with radiation alone. It typically responds well but returns, and over time it can transform into a faster growing lymphoma, most often DLBCL. Since 2022 the FDA has approved bispecific antibodies and, in 2024, CAR T cell therapy for relapsed follicular lymphoma. Other lymphomas are on our lymphoma clinical trials page.
Types of follicular lymphoma clinical trials
Chemotherapy free trials. Bispecific antibodies with or without lenalidomide compared with standard chemoimmunotherapy as first or second treatment.
Relapsed disease trials. New drugs and combinations for lymphoma that returns, especially within two years.
CAR T and cellular trials. Engineered immune cells for people after several prior treatments; see CAR T cell therapy clinical trials.
Watch and wait studies. Whether early treatment helps people with low tumor burden.
Transformation research. Studies of what drives transformation to aggressive lymphoma and how to treat it.
New to research? Read how clinical trials for cancer work.
Who can participate in follicular lymphoma clinical trials?
Trials sort by whether you have had treatment and how many lines. First treatment trials often require that treatment is now needed, not watch and wait; relapsed trials specify the number of prior lines, often two or more, and whether your lymphoma returned within two years. Most require biopsy confirmed grade 1 to 3a follicular lymphoma, adequate organ function, and the ability to manage daily activities. Eligibility always varies by study.
Stages and risk in follicular lymphoma, and why they matter for trials
Early stage (I to II). Limited to one area; may be treated with radiation alone, and trials are fewer.
Advanced stage (III to IV), low burden. Often watched without treatment; some trials test early treatment.
Advanced stage, needing treatment. Symptoms or high tumor burden; most first line trials enroll here.
Relapsed or refractory. Returned or not responding; the setting for bispecific, CAR T, and new drug trials, especially for early relapse.
Do follicular lymphoma trial participants get paid?
Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
Curious whether clinical trials pay participants? Here's how compensation actually works.
How to enroll in a follicular lymphoma clinical trial
Identify your trial. Use the filters and match the stage or type and the treatment history named in study titles to your own.
Select your preferred location. Enter your city or state; large trials run at many sites, early phase studies at fewer centers.
Explore study details. Click "Learn More" for eligibility, prior treatment rules, and the visit schedule.
Complete the health profile. Click "Get started" to begin the 5-step application. Have three things ready: your stage and grade, the treatments you have had and when the lymphoma returned, and whether a transformation was suspected.
Submit the application. A clinical trial coordinator reviews it and contacts you. Nothing is decided until informed consent, and participation is voluntary at every step.